Searched for
AURIGENE ONCOLOGY
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Most difficult: Staying invested in businesses while ignoring noise called Gulf war; 19 stocks from different sectors to ‘hold’Businesses that create long-term wealth are those where the demand runway is long, the competitive position is strong, and the management i...
- Will the currency cycle help them? Yes, but very selectively: 10 pharma stocks with upside potential of up to 33%The biggest mistake made in currency cycles is to confuse revenue gain with pure earnings gain. A company may report stronger rupee revenue...
- China’s India headache: The growing pharmaceutical industryIndian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring trend and a desir...
- Trump & Tariffs: Pharma sector might escape the inevitable tariff troubles. 6 pharma stocks, 5 with an upside potential of up to 38%Exactly eight years ago, in 2016, when a reality TV star became US president, the global markets went into sharp decline on the day of surp...
- In volatile times, defensive stocks or defensive businesses? The two are different. 7 stocks from second category with an upside potential of up to 32%Last Friday was probably the sixth time in 2024 that practically all sectoral indices were in the red. Needless to say, the market breadth ...
- Stocks in news: Adani Green, Infosys, Torrent Power, Dr Reddy's, JSW InfraThe IT services company expanded its four year collaboration with Old National Bank to accelerate the Bank’s operational and technological ...
- Aurigene reports promising phase-1 data for its CAR-T therapy against myelomaAurigene Oncology has announced promising phase-1 results for its novel CAR-T cell therapy, Ribrecabtagene autoleucel, in patients with mul...
- The yen connection: 4 Indian pharma stocks which benefit from the strength of Japanese yen with an upside potential of up to 15%Every event in the currency market has a twin impact, while some lose but there are others which also gain. But given the mayhem on the str...
- These healthcare and pharma stocks may deliver more than 20% in one yearCheck out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focu...
- Defensive bet with macro tailwinds? 5 Indian pharma stocks with upside potential of up to 20%On Tuesday, when the whole market was reeling under pressure, two stocks reacted to their numbers in a positive direction. Both of them wer...
- Getting back into shape? 6 Indian pharma stocks with upside potential of up to 41%The year 2024, started with a correction in nifty, but one set of stocks which were able to outperform were pharma stocks. While it might a...
- Aurigene inks drug discovery, development pact with US-based EQRxUnder the terms of the collaboration agreement, Aurigene and EQRx will collaborate on drug discovery, pre-clinical and clinical development...
- Dr Reddy's Laboratories planning mergers and acquisitions to climb up ladderIndia contributed about a fifth or ₹4,196 crore of the company's overall sales of ₹21,439 crore in 2021-22, but domestic business has clock...
- Dr Reddy's arm inks pact with US-based Olema PharmaceuticalsAurigene will also be eligible for up to USD 60 million in potential clinical development and regulatory milestones and up to USD 370 milli...
- Like IT sector in the past, everything's coming together for pharma now: GV PrasadIndia is well positioned to be a dominant force in the global generics industry and that is showing.
- Medical breakthrough! Aurigene closer to developing cancer treatment capsuleThe Bengaluru-based company is an independent subsidiary of Dr Reddy’s Laboratories and its United States-based partner Curis Inc.
- DRL's Aurigene ties up with US firm CurisCuris has agreed to make payments of up to $52.5 million per programme including $42.5 million for approval and commercial milestones,
- India's drug discovery and development: Small research firms aim to change face of cancer therapyIndia is not known for developing drugs, let along cancer drugs, but a few small and niche firms are trying exactly that, reports ET.
Load More
